|

GV20-0251 and Pembrolizumab [KEYTRUDA®] Clinical Trials

1 actively recruiting trial across 1 location

Also known as: MK-3475

Pipeline

Phase 1/2: 1

Top Sponsors

  • GV20 Therapeutics1

Indications

  • pMMR/MSS Adenocarcinoma of the Colon or Rectum1
  • Squamous Head and Neck Carcinoma1
  • Endometrial Carcinoma (EC)1
  • Refractory Cancer1
  • Cutaneous Melanoma1

Los Angeles, California1 trial

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

The Angeles Clinic and Research Institute

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.